A5102953783- Asthma and respiratory diseases
- Chronic Obstructive Pulmonary Disease (COPD) Research
- Respiratory and Cough-Related Research
- Inhalation and Respiratory Drug Delivery
- Respiratory Support and Mechanisms
- Cystic Fibrosis Research Advances
- Air Quality and Health Impacts
- Neonatal Respiratory Health Research
- Pediatric health and respiratory diseases
- Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis
- Delphi Technique in Research
- Pharmaceutical studies and practices
- Analytical Methods in Pharmaceuticals
GlaxoSmithKline (United Kingdom)
2007-2022
Salford Royal NHS Foundation Trust
2017
University of Manchester
2017
University of Southampton
2017
GlaxoSmithKline (Netherlands)
2013
Wellcome Library
1998
Evidence for the management of chronic obstructive pulmonary disease (COPD) comes from closely monitored efficacy trials involving groups patients who were selected on basis restricted entry criteria. There is a need randomized to be conducted in conditions that are closer usual clinical practice.In controlled effectiveness trial 75 general practices, we randomly assigned 2799 with COPD once-daily inhaled combination fluticasone furoate at dose 100 μg and vilanterol 25 (the...
Objective To compare the effects of switching from a pressurised metered dose inhaler (pMDI)-based to dry powder (DPI)-based maintenance therapy versus continued usual care on greenhouse gas emissions (carbon dioxide equivalents, CO 2 e) and asthma control. Methods This post-hoc analysis was based subset 2236 (53%) patients Salford Lung Study in Asthma who at baseline were using pMDI-based controller therapy. During study randomised fluticasone furoate/vilanterol (FF/VI) via ELLIPTA DPI...
Combination therapy with an inhaled corticosteroid (ICS) and long-acting β2 agonist (LABA) is recommended for patients asthma symptomatic on ICS alone. However, there ongoing debate regarding the risk-benefit ratio of using LABA in asthma.To evaluate effect addition a novel LABA, vilanterol (VI), to once-daily ICS, fluticasone furoate (FF), risk severe exacerbations uncontrolled asthma.This randomised double-blind comparative study variable duration (≥ 24-78 weeks) was designed finish after...
Inhaled corticosteroids are the recommended first-line treatment for asthma but adherence to therapy is suboptimal. The objectives of this study were compare efficacy and safety once-daily (OD) evening twice-daily (BD) regimens novel inhaled corticosteroid fluticasone furoate (FF) in patients. Patients with moderate (age ≥ 12 years; pre-bronchodilator forced expiratory volume 1 second (FEV1) 40-85% predicted; FEV1 reversibility 12% 200 ml) randomized FF or propionate (FP) a double-blind,...
Background: Using a composite measure based on clinical outcomes, the GOAL study showed that achievement of Total Control asthma was time dependent with proportion controlled patients continuing to rise through year-long study. Taking data from this study, we compared taken achieve total control each individual criterion treatment salmeterol/fluticasone propionate (SFC) or fluticasone (FP) alone. Methods: Time achieving outcomes (day-time symptoms, night-time awakenings, rescue medication...
Fluticasone furoate (FF)/vilanterol (VI) is a once-daily inhaled corticosteroid (ICS)/long-acting beta2 agonist (LABA) combination. FF/VI, 92/22mcg and 184/22mcg, are approved in Europe as maintenance therapy persistent asthma. We report data from mixed treatment comparisons (MTC) of FF/VI against established twice-daily ICS/LABA combination therapies on clinical efficacy outcomes. Data 31 parallel-group randomised controlled trials (RCTs) ICS/LABA, ≥8 weeks' duration patients aged ≥12 years...
<h3>Introduction and objectives</h3> ICS of differing particle size, due both to the formulation propellant, may impact patient outcomes. This systematic review randomised controlled trials compared asthma efficacy safety outcomes from use fluticasone propionate (FP)-containing medications alternative smaller ICS. <h3>Methods</h3> English language published peer-reviewed literature (Jan 1, 1998-Feb 13, 2014) with FP-containing medications, yielded 1,655 potentially-relevant articles: 1,575...
<h3>Background</h3> GOLD 2017 separates spirometric staging from the 'ABCD' groupings defined by symptom burden/exacerbation risk. SLS COPD, a 12 month randomised controlled trial, demonstrated effectiveness and safety of initiating fluticasone furoate/vilanterol versus continuing usual care in COPD patients UK primary (Vestbo J et al, New Engl Med 2016;375:1253–60). <h3>Aim</h3> Map patient distribution treatment patterns to classification grid. <h3>Methods</h3> In this post-hoc analysis,...